Researchers have established clinical indications for pediatric blood transfusions with various ABO/Rh blood types that emphasize Rh compatibility.

Elevated basal serum tryptase levels in SM and HαT, as well as overlapping clinical characteristics, complicate the diagnostic process for both disorders.

Frailty reduced the likelihood of CLL/SLL first-line treatment initiation during the CIT era, but the gap narrowed with novel therapies.

Long-term prophylaxis with lanadelumab has been linked to a marked reduction in attack rates in HAE, with the decline persisting in a real-world setting.

Compound 23, a dual-target FGFR2/3 inhibitor, delivered superior growth improvements over infigratinib in achondroplasia mouse models.

Biomarkers are increasingly recognized for their use in diagnosing and tracking disability progression in NMOSD.

Researchers developed a new clinical score to estimate the probability of NMOSD in patients presenting with optic neuritis.

Researchers have identified a set of microRNAs that may serve as biomarkers for diagnosing granulomatosis with polyangiitis (GPA), a form of AAV.

In multivariable analysis, only del(11q)—not ATM mutation—was independently associated with high risk for early disease progression in CLL.

Novel findings in the pathophysiology of HD could unlock a new imaging-based marker for disease burden and clinical decline, a study found.

Two phase 3 clinical trials are recruiting patients with CIDP to evaluate the efficacy of riliprubart treatment.

With a $48 billion annual budget, the US National Institutes of Health is the world’s largest public funder of biomedical research.